Brookline Capital
Brookline Capital (1.89)
Rank
#117 (of 499)
Total Ratings
48
Success Rate
Average Return
31 Covered Stocks
| Company | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CCCC C4 Therapeutics, Inc. | Maintain: Buy | 30 | 3.3 | 809.09% | 2 | Feb 22, 2026 | |
LSTA Lisata Therapeutics, Inc. | Downgrade: Hold | n/a | 1.56 | n/a | 2 | Jan 20, 2026 | |
RNTX Rein Therapeutics Inc. | Downgrade: Hold | n/a | 0.79 | n/a | 2 | Jan 20, 2026 |
Pro Membership
Stop Guessing, Start Knowing.
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
Unlimited access
Unlimited access to all data and tools, giving you the edge over everyone else in the market.
Proprietary Stock Rating Score
Evaluate stocks with our proprietary rating score based on fundamentals, economic moat, and sentiment.
Top Wall Street Analyst Ratings
Follow ratings from the best analysts on Wall Street to stay ahead of market moves.
Up to 30 years financial history
We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.